Infliximab for Injection

Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.

Compare

Category: Uncategorized

Description
Reviews (0)

The first infliximab biosimilar marketed in China

Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.

Indications:

Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.

Recommended reading

Infliximab biosimilar manufacturer in China